Abstract:Heat shock factor 1 (HSF1) enhances the survival of cancer cells under various stresses. The knock-out of HSF1 impairs cancer formation and progression, suggesting that HSF1 is a promising therapeutic target. To identify inhibitors of HSF1 activity, we performed cell-based screening with a library of marketed and experimental drugs and identified cantharidin as an HSF1 inhibitor. Cantharidin is a potent antitumor agent from traditional Chinese medicine. Cantharidin inhibited heat shock-induced luciferase activity with an IC50 of 4.2 μm. In contrast, cantharidin did not inhibit NF-κB luciferase reporter activity, demonstrating that cantharidin is not a general transcription inhibitor. When the HCT-116 colorectal cancer cells were exposed to heat shock in the presence of cantharidin, the induction of HSF1 downstream target proteins, such as HSP70 and BAG3 (Bcl-2-associated athanogene domain 3), was suppressed. HSP70 and its co-chaperone BAG3 have been reported to protect cells from apoptosis by stabilizing anti-apoptotic Bcl-2 family proteins. As expected, treating HCT-116 cancer cells with cantharidin significantly decreased the amounts of BCL-2, BCL-xL, and MCL-1 protein and induced apoptotic cell death. Chromatin immunoprecipitation analysis showed that cantharidin inhibited the binding of HSF1 to the HSP70 promoter and subsequently blocked HSF1-dependent p-TEFb recruitment. Therefore, the p-TEFb-dependent phosphorylation of the C-terminal domain of RNA polymerase II was blocked, arresting transcription at the elongation step. Protein phosphatase 2A inhibition with PP2CA siRNA or okadaic acid did not block HSF1 activity, suggesting that cantharidin inhibits HSF1 in a protein phosphatase 2A-independent manner. We show for the first time that cantharidin inhibits HSF1 transcriptional activity.

Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A

Apoptotic Activity of a Novel Synthetic Cantharidin Analogue on Hepatoma Cell Lines

Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS Via Mitochondria-Dependent Pathway.

Insights into the Key Interactions Between Human Protein Phosphatase 5 and Cantharidin Using Molecular Dynamics and Site-Directed Mutagenesis Bioassays

Synthesis and Biological Evaluation of Norcantharidin Derivatives As Protein Phosphatase-1 Inhibitors.

Mechanistic Insight Into A Novel Synthetic Cantharidin Analogue In A Leukaemia Model

A Synthetic Cantharidin Analog for the Enhancement of Doxorubicin Suppression of Stem Cell-Derived Aggressive Sarcoma

Apoptogenic Activity of a Synthetic Cantharimide in Leukaemia: Implication on Its Structural Activity Relationship.

Abstract. Cantharidin is an active constituent of mylabris, a traditional Chinese therapeutic agent. Cantharidin is a potent and selective inhibitor of protein phosphatase 2A (PP2A)

Analysis of Gene Expression Profiles in Human Hl-60 Cell Exposed to Cantharidin Using Cdna Microarray

The natural compound cantharidin induces cancer cell death through inhibition of heat shock protein 70 (HSP70) and Bcl-2-associated athanogene domain 3 (BAG3) expression by blocking heat shock factor 1 (HSF1) binding to promoters

Conjugates of podophyllotoxin and norcantharidin as dual inhibitors of topoisomeraseⅡ and protein phosphatase 2A.

Research Progress on the Antitumor Mechanisms of Cantharidin and Its Derivatives

Hepatotoxic mechanism of cantharidin: insights and strategies for therapeutic intervention

Progress and Application of Cantharidin and Its Derivatives

Bibliometric Analysis and Systemic Review of Cantharidin Research Worldwide

Anticancer Attributes of Cantharidin: Involved Molecular Mechanisms and Pathways

PP2A Inhibitors Suppress Migration and Growth of PANC-1 Pancreatic Cancer Cells Through Inhibition on the Wnt/β-catenin Pathway by Phosphorylation and Degradation of Β-Catenin

Catalytic Inactivation of Alkaline Phosphatase by Cantharidin, an Inhibitor of Protein Phosphatase